Abstract 1481P
Background
Reportedly up to 30% of lung cancer patients will develop hemoptysis and 10% will experience massive hemoptysis. Bronchial artery embolization (BAE) is routinely performed in patients with hemoptysis secondary to neoplasm, while associated with a high failure rate and increased mortality. The aim of this study was to compare the efficacy of drug-eluting microspheres BAE (DEM-BAE) with blank microspheres BAE (BM-BAE) for hemoptysis in NSCLC patients.
Methods
DEM-BAE was performed in 25 patients with hemoptysis with one vial of 300-500μm Callispheres drug-eluting beads (Gemcitabine 100mg). The BM-BAE group consisted of 25 patients who were treated with blank microspheres of 300-500μm. We categorized the results as technical and clinical success, and also included the mid-term results. Technical success was defined as the complete cessation of the target artery as confirmed by digital subtraction angiography (DSA). Clinical success was defined as the cessation of hemoptysis within 24 h of BAE. Technical success was compared immediately after the procedure. The clinical success and mid-term results (percentage of patients who were free of hemoptysis) were compared at 1 and 6 months after the procedure, respectively.
Results
There was no significant difference for technical success rates (DEM-BAE group: 90%, BM-BAE group: 85%, P>0.05). However, the clinical success rates (DEM-BAE group: 83.3%, BM-BAE group: 68%, P<0.01) and the mid-term results (DEM-BAE group: 71.4%, BM-BAE group: 64%, P<0.01) showed a significant difference. Moreover, Disease control rate (CR+PR+SD) was higher in DEM-BAE group than control group (DEM-BAE group: 78.5%, BM-BAE group: 48%, P<0.01). The procedure-related complications included mild cough and mild chest pain. There was no special management required for these complications.
Conclusions
DEM-BAE appeared to be the more optimal modality to improve the mid-term clinical efficacy compared to blank microspheres BAE for hemoptysis in NSCLC patients. Further studies were warranted.
Clinical trial identification
ChiCTR2300071106.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1199P - Developing and systematically validating homologous recombination repair gene detection method based on next-generation sequencing
Presenter: Yi Sun
Session: Poster session 10
1200P - Investigation of multiphoton microscopy as an innovative tool for intraoperative section-free histologic investigations in just a few minutes
Presenter: Martí Homs Soler
Session: Poster session 10
1201P - Novel deep learning model and validation of whole slide images in lung cancer diagnosis
Presenter: Alhassan Ahmed
Session: Poster session 10
Resources:
Abstract
1202P - A deep learning approach using routine pathology images to guide precision medicine in metastatic CRC
Presenter: Chaitanya Parmar
Session: Poster session 10
1203P - Analytical evaluation of whole genome sequencing for acute myeloid leukemia
Presenter: Guidantonio Malagoli Tagliazucchi
Session: Poster session 10
1204P - Real-world utility of whole genome sequencing for patients with cancer: Evaluation of a regional implementation of the 100,000 genomes project
Presenter: Helen Robbins
Session: Poster session 10
1205P - A retrospective machine learning-based analysis of nationwide cancer CGP data across cancer types to identify features associated with recommendation of mutation-based therapy
Presenter: Hiroaki Ikushima
Session: Poster session 10
1478P - Dual single-nucleotide polymorphism biomarker combination to select opioid for cancer pain management
Presenter: Yoshihiko Fujita
Session: Poster session 10
1479P - Use of rescue opioids and pain control after ketamine initiation in refractory cancer pain: A multicentric observational study
Presenter: Pablo Gallardo Melo
Session: Poster session 10
1480P - Long term therapy with denosumab and zoledronic acid: A comparative real-world retrospective observational study on skeletal-related events and pain in patients with metastatic breast cancer
Presenter: Giacomo Massa
Session: Poster session 10